Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

SPECIALTY TOPICS

CURRENTLY VIEWING
Mantle Cell Lymphoma

Multiple Myeloma

Lung Cancer

Immuno-Oncology News

Gynecologic Oncology

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Mantle Cell Lymphoma

Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL

$Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL$

China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the...
Read More >>

MCL Paradigm Moves Toward More Nuanced Risk Stratification, Novel Treatments

ASCO 2020: KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL

Venetoclax Shows Marked Responses and Distinct Resistance Mechanisms in MCL

Precision Medicine: The Next Paradigm Shift in MCL

MCL Treatments Step Away From Chemotherapy, Closer to a Cure

View More Stories >>

View Conference Coverage

2020 ASCO Direct Highlights

2020 ESMO Breast Cancer Virtual Meeting

2020 ASCO Virtual Scientific Program

2020 International Symposium on Ovarian Cancer and Other Gynecologic Malignancies

2020 AACR Annual Meeting

Dr. Karmali on Limitations of Intensive Therapy in Older/Medically Unfit Patients With MCL

Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

$Dr. Jain on Response and Resistance to Venetoclax in Relapsed/Refractory MCL$

$Dr. Smith on Ongoing Research in Relapsed/Refractory MCL$

OncLive houses thousands of videos that provide updates and information.
See more Videos

Noteworthy Data on MCL: ASH 2019

CAR T-Cell Therapy for MCL

Challenges in Treating R/R MCL

Patient Selection Among FDA Approved BTK Inhibitors

Differences Among BTK Inhibitors for MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

First-Generation BTK Inhibition in Mantle Cell Lymphoma

Advice for Future Management of Mantle Cell Lymphoma

Non-BTKi Agents' Role in Mantle Cell Lymphoma

MCL: Novel BTK Inhibitor Combination Strategies

$Identifying Unmet Needs in Relapsed/Refractory MCL$

Differentiating BTK Inhibitor Mechanisms of Action in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Ibrutinib in Relapsed Mantle Cell Lymphoma

Drs Danilov, Goy, Leonard, Pagel, and Schuster, discuss ibrutinib (Imbruvica) as a treatment in relapsed mantle cell lymphoma. View Now

Treatments for Relapsed Mantle Cell Lymphoma

Brad S. Kahl, MD, and Richard R. Furman, MD, explain available treatment options for relapsed mantle cell lymphoma. View Now

Featured Webinar

OncLive Saturday Spotlight: A Morning With Weill Cornell Medicine

An OncLive This week, we have collaborated with Weill Cornell Medicine to highlight important topics facing oncologists today. Join us Saturday, June 6, 2020 at 11 AM EST. View more

ASCO 2020 News

Gina Columbus recaps on the latest news and speaks with leading oncologists from the 2020 ASCO Virtual Scientific Program.